In vivo pain relief effectiveness of an analgesic-anesthetic carrying biodegradable controlled release rod systems.
Pain is the most common and feared symptom for patients, especially those with cancer. Treatment of chronic pain with conventional ways of medication usually fails with increasing severity of the pain. New approaches enabling the prolonged provision of pain relievers are required. We designed a controlled release system of pain relievers, mainly for opioids (morphine, M, codeine, C, and hydromorphone, HM), and a local anesthetic (bupivacaine, BP) in the form of poly(L-lactide-co-glycolide) (PLGA) rods. The efficacy of these rods implanted alone or in combination in relieving chronic pain in rats caused by the ligation of the sciatic nerve of their right hind limbs was studied. The two most common tests for measuring analgesia, i.e. tail-flick tests, that show analgesia at sites other than the site of injury, were used to study the degree of systemic distribution of the drugs and paw-withdrawal tests were used to study the analgesia at the site of injury. Alleviation of this chronic and severe neuropathic pain could be obtained for about 3-4 days when rods for two drugs, 'dual drug' (analgesic-anesthetic), were used. This duration is decreased by half (2 days) with the single-drug rods. Also the dual-drug rods, though at half the dose of each single drug application, enhanced the degree of analgesia of the first day. These in vivo results are also consistent with the previous in vitro results as in the case with codeine which had a higher first-day analgesia than morphine, despite a lower potency due to the faster in vitro release rate. Similarly, slower release of hydromorphone from PLGA (85:15) rods resulted in less systemic analgesia than the more rapidly eroding PLGA (50:50) rods of the same drug.
Sendil-Keskin
D
D
Middle East Technical University, Department of Biological Sciences and Biotechnology, Biotechnology Research Unit, 06531 Ankara, Turkey.
Altunay
H
H
Wise
D L
DL
Hasirci
V
V
D000701:Analgesics, Opioid / Q000008:administration & dosage*; D000779:Anesthetics, Local / Q000008:administration & dosage*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001672:Biocompatible Materials; D001673:Biodegradation, Environmental; D002045:Bupivacaine / Q000008:administration & dosage; D003061:Codeine / Q000008:administration & dosage / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods; D004343:Drug Implants / Q000008:administration & dosage*; D005260:Female; D004091:Hydromorphone / Q000008:administration & dosage; D019344:Lactic Acid / Q000737:chemistry / Q000378:metabolism; D009020:Morphine / Q000008:administration & dosage; D010146:Pain / Q000188:drug therapy*; D011100:Polyglycolic Acid / Q000737:chemistry / Q000378:metabolism; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D000701:Analgesics, Opioid; D000779:Anesthetics, Local; D001672:Biocompatible Materials; D004343:Drug Implants; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D009020:Morphine; D004091:Hydromorphone; D003061:Codeine; D002045:Bupivacaine